A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva

A gynecologic oncology group study

David H. Moore, Shamshad Ali, Wui Jin Koh, Helen Michael, MacK N. Barnes, Carolyn K. McCourt, Howard D. Homesley, Joan L. Walker

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Objectives: To determine the efficacy and toxicity of radiation therapy and concurrent weekly cisplatin chemotherapy in achieving a complete clinical and pathologic response when used for the primary treatment of locally-advanced vulvar carcinoma. Methods: Patients with locally-advanced (T3 or T4 tumors not amenable to surgical resection via radical vulvectomy), previously untreated squamous cell carcinoma of the vulva were treated with radiation (1.8 Gy daily × 32 fractions = 57.6 Gy) plus weekly cisplatin (40 mg/m 2) followed by surgical resection of residual tumor (or biopsy to confirm complete clinical response). Management of the groin lymph nodes was standardized and was not a statistical endpoint. Primary endpoints were complete clinical and pathologic response rates of the primary vulvar tumor. Results: A planned interim analysis indicated sufficient activity to reopen the study to a second stage of accrual. Among 58 evaluable patients, there were 40 (69%) who completed study treatment. Reasons for prematurely discontinuing treatment included: patient refusal (N = 4), toxicity (N = 9), death (N = 2), other (N = 3). There were 37 patients with a complete clinical response (37/58; 64%). Among these women there were 34 who underwent surgical biopsy and 29 (78%) who also had a complete pathological response. Common adverse effects included leukopenia, pain, radiation dermatitis, pain, or metabolic changes. Conclusions: This combination of radiation therapy plus weekly cisplatin successfully yielded high complete clinical and pathologic response rates with acceptable toxicity.

Original languageEnglish
Pages (from-to)529-533
Number of pages5
JournalGynecologic Oncology
Volume124
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Vulva
Cisplatin
Squamous Cell Carcinoma
Radiotherapy
Drug Therapy
Radiodermatitis
Treatment Refusal
Biopsy
Radiation Dosage
Pain
Groin
Leukopenia
Residual Neoplasm
Neoplasms
Therapeutics
Lymph Nodes
Carcinoma

Keywords

  • Chemotherapy
  • Radiation therapy
  • Surgery
  • Vulva cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva : A gynecologic oncology group study. / Moore, David H.; Ali, Shamshad; Koh, Wui Jin; Michael, Helen; Barnes, MacK N.; McCourt, Carolyn K.; Homesley, Howard D.; Walker, Joan L.

In: Gynecologic Oncology, Vol. 124, No. 3, 03.2012, p. 529-533.

Research output: Contribution to journalArticle

Moore, David H. ; Ali, Shamshad ; Koh, Wui Jin ; Michael, Helen ; Barnes, MacK N. ; McCourt, Carolyn K. ; Homesley, Howard D. ; Walker, Joan L. / A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva : A gynecologic oncology group study. In: Gynecologic Oncology. 2012 ; Vol. 124, No. 3. pp. 529-533.
@article{21830c5d6bc8494d84eb724de472d4b0,
title = "A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: A gynecologic oncology group study",
abstract = "Objectives: To determine the efficacy and toxicity of radiation therapy and concurrent weekly cisplatin chemotherapy in achieving a complete clinical and pathologic response when used for the primary treatment of locally-advanced vulvar carcinoma. Methods: Patients with locally-advanced (T3 or T4 tumors not amenable to surgical resection via radical vulvectomy), previously untreated squamous cell carcinoma of the vulva were treated with radiation (1.8 Gy daily × 32 fractions = 57.6 Gy) plus weekly cisplatin (40 mg/m 2) followed by surgical resection of residual tumor (or biopsy to confirm complete clinical response). Management of the groin lymph nodes was standardized and was not a statistical endpoint. Primary endpoints were complete clinical and pathologic response rates of the primary vulvar tumor. Results: A planned interim analysis indicated sufficient activity to reopen the study to a second stage of accrual. Among 58 evaluable patients, there were 40 (69{\%}) who completed study treatment. Reasons for prematurely discontinuing treatment included: patient refusal (N = 4), toxicity (N = 9), death (N = 2), other (N = 3). There were 37 patients with a complete clinical response (37/58; 64{\%}). Among these women there were 34 who underwent surgical biopsy and 29 (78{\%}) who also had a complete pathological response. Common adverse effects included leukopenia, pain, radiation dermatitis, pain, or metabolic changes. Conclusions: This combination of radiation therapy plus weekly cisplatin successfully yielded high complete clinical and pathologic response rates with acceptable toxicity.",
keywords = "Chemotherapy, Radiation therapy, Surgery, Vulva cancer",
author = "Moore, {David H.} and Shamshad Ali and Koh, {Wui Jin} and Helen Michael and Barnes, {MacK N.} and McCourt, {Carolyn K.} and Homesley, {Howard D.} and Walker, {Joan L.}",
year = "2012",
month = "3",
doi = "10.1016/j.ygyno.2011.11.003",
language = "English",
volume = "124",
pages = "529--533",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva

T2 - A gynecologic oncology group study

AU - Moore, David H.

AU - Ali, Shamshad

AU - Koh, Wui Jin

AU - Michael, Helen

AU - Barnes, MacK N.

AU - McCourt, Carolyn K.

AU - Homesley, Howard D.

AU - Walker, Joan L.

PY - 2012/3

Y1 - 2012/3

N2 - Objectives: To determine the efficacy and toxicity of radiation therapy and concurrent weekly cisplatin chemotherapy in achieving a complete clinical and pathologic response when used for the primary treatment of locally-advanced vulvar carcinoma. Methods: Patients with locally-advanced (T3 or T4 tumors not amenable to surgical resection via radical vulvectomy), previously untreated squamous cell carcinoma of the vulva were treated with radiation (1.8 Gy daily × 32 fractions = 57.6 Gy) plus weekly cisplatin (40 mg/m 2) followed by surgical resection of residual tumor (or biopsy to confirm complete clinical response). Management of the groin lymph nodes was standardized and was not a statistical endpoint. Primary endpoints were complete clinical and pathologic response rates of the primary vulvar tumor. Results: A planned interim analysis indicated sufficient activity to reopen the study to a second stage of accrual. Among 58 evaluable patients, there were 40 (69%) who completed study treatment. Reasons for prematurely discontinuing treatment included: patient refusal (N = 4), toxicity (N = 9), death (N = 2), other (N = 3). There were 37 patients with a complete clinical response (37/58; 64%). Among these women there were 34 who underwent surgical biopsy and 29 (78%) who also had a complete pathological response. Common adverse effects included leukopenia, pain, radiation dermatitis, pain, or metabolic changes. Conclusions: This combination of radiation therapy plus weekly cisplatin successfully yielded high complete clinical and pathologic response rates with acceptable toxicity.

AB - Objectives: To determine the efficacy and toxicity of radiation therapy and concurrent weekly cisplatin chemotherapy in achieving a complete clinical and pathologic response when used for the primary treatment of locally-advanced vulvar carcinoma. Methods: Patients with locally-advanced (T3 or T4 tumors not amenable to surgical resection via radical vulvectomy), previously untreated squamous cell carcinoma of the vulva were treated with radiation (1.8 Gy daily × 32 fractions = 57.6 Gy) plus weekly cisplatin (40 mg/m 2) followed by surgical resection of residual tumor (or biopsy to confirm complete clinical response). Management of the groin lymph nodes was standardized and was not a statistical endpoint. Primary endpoints were complete clinical and pathologic response rates of the primary vulvar tumor. Results: A planned interim analysis indicated sufficient activity to reopen the study to a second stage of accrual. Among 58 evaluable patients, there were 40 (69%) who completed study treatment. Reasons for prematurely discontinuing treatment included: patient refusal (N = 4), toxicity (N = 9), death (N = 2), other (N = 3). There were 37 patients with a complete clinical response (37/58; 64%). Among these women there were 34 who underwent surgical biopsy and 29 (78%) who also had a complete pathological response. Common adverse effects included leukopenia, pain, radiation dermatitis, pain, or metabolic changes. Conclusions: This combination of radiation therapy plus weekly cisplatin successfully yielded high complete clinical and pathologic response rates with acceptable toxicity.

KW - Chemotherapy

KW - Radiation therapy

KW - Surgery

KW - Vulva cancer

UR - http://www.scopus.com/inward/record.url?scp=84856696176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856696176&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2011.11.003

DO - 10.1016/j.ygyno.2011.11.003

M3 - Article

VL - 124

SP - 529

EP - 533

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -